ALLMedicine™ Acquired Hemophilia A Center
Research & Reviews 109 results
Hematology/oncology Clinics of North America; Pai M
Sep 19th, 2021 - Acquired hemophilia A is a potentially severe bleeding disorder caused by antibodies against the patient's own factor VIII. Acquired hemophilia A is rare. It is most commonly diagnosed in older individuals; about one-half of cases of acquired hemo...
Blood Advances; Mingot-Castellano ME, Pardos-Gea J et. al.
Sep 15th, 2021 - The Spanish Acquired Hemophilia A (AHA) Registry is intended to update the status of AHA in Spain. One hundred and fifty-four patients were included and retrospectively followed-up for a median time of 12 months. Patients were predominantly male (...
https://doi.org/10.1007/s12185-021-03212-9 10.1182/blood-2006-06-029850 10.1182/blood-2012-02-408930 10.1002/9780470757260.ch16 10.1016/S0950-3536(98)80049-8 10.1186/1756-0500-3-161 10.1111/hae.12138 10.2491/jjsth.19.140 10.1111/bjh.12091 10.1055/s-0038-1653759 10.1111/j.1365-2516.2008.01924.x 10.1007/s12185-019-02674-2 10.2491/jjsth.29.251 10.1111/j.1365-2516.2008.01785.x 10.26420/annhematoloncol.2017.1173 10.2169/internalmedicine.9150-17 10.1007/s00277-012-1485-3 10.1007/s12185-020-02983-x 10.1111/jth.13304 10.1055/s-0039-1692427 10.1182/bloodadvances.2017011536 10.1182/blood-2014-09-598268 10.1182/blood.V89.10.3663 10.1016/S0049-3848(00)00418-7 10.1111/j.1538-7836.2004.00802.x 10.1182/blood-2016-11-751347 10.1182/blood-2016-02-701805 10.1111/ejh.13249
International Journal of Hematology; Ieko M, Ohmura K et. al.
Sep 4th, 2021 - Coagulation factor inhibitors (CFIs) sometimes cause fatal bleeding conditions. Determination of an inhibitor titer (INH-titer) using the Bethesda method is essential for diagnosing diseases associated with CFIs and examining the effects of immuno...
Journal of Thrombosis and Haemostasis : JTH; Bonnefoy A, Merlen C et. al.
Aug 30th, 2021 - Acquired hemophilia A (AHA) is a potentially life-threatening bleeding disorder caused by factor VIII (FVIII) autoantibodies, involving various immunoglobulin (Ig) isotypes and IgG subclasses. We analyzed the profile of Ig against FVIII in patient...
Medicine Wang LY, Shen Y et. al.
Aug 17th, 2021 - Poor availability and a lack of affordability of bypassing agents (recombinant activated factor VII and activated prothrombin complex concentrate) in west China prompted us to investigate an alternative cost-effective combination therapy. We aimed...
Drugs 5 results see all →
News 11 results
Aug 1st, 2019 - FACTOR VIII INHIBITOR EVALUATION 2. What is the most likely underlying condition associated with this patient’s factor VIII inhibitor? Autoimmune disease Malignancy A medication Unknown (idiopathic) Acquired hemophilia A (AHA) is a rare disorder c.
May 22nd, 2019 - The FVIII/W (factor VIII:C/von Willebrand factor antigen) ratio appears to be a reliable biological marker to predict recovery and/or relapse in patients with acquired hemophilia A, according to a retrospective analysis. Marc Trossaert, MD, PhD, o.
Mar 13th, 2019 - Measurement of factor XIII levels, followed by replacing deficiencies if found, may help to achieve sustained hemostasis in the management of bleeding in patients with acquired hemophilia A. Jameel Abdulrehman, MD, of the University of Toronto in.
Nov 23rd, 2015 - Trends-in-Medicine (access restricted) dug up details on the proposed CMS coverage restrictions for the Watchman left atrial appendage (LAA) closure device, which revealed that: The agency is likely to clarify its requirement that patients not be ...
Nov 15th, 2015 - Vial of Obizur Photo courtesy of Baxter International Inc. The European Commission (EC) has approved a recombinant porcine factor VIII (FVIII) product, Obizur, to treat bleeding episodes in adults with acquired hemophilia A caused by autoantibodie.